[
  {
    "ts": null,
    "headline": "How Analyst Views Are Shaping the Evolving Story for AbbVie",
    "summary": "AbbVie’s consensus analyst price target has inched up from $237.48 to $241.29, reflecting renewed optimism surrounding the stock’s outlook. This slight boost is attributed to strong sales for core immunology treatments and an extended exclusivity window for Rinvoq, in addition to ongoing strategic developments. As analysts evaluate these catalysts alongside lingering concerns, readers should stay tuned for insights on monitoring evolving opinions and updates in the months ahead. Stay updated...",
    "url": "https://finnhub.io/api/news?id=267bd91fae4eeee3938dcab4caaa3ee235f892f5cf537d8514ca1df38202b8cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762790712,
      "headline": "How Analyst Views Are Shaping the Evolving Story for AbbVie",
      "id": 137396598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s consensus analyst price target has inched up from $237.48 to $241.29, reflecting renewed optimism surrounding the stock’s outlook. This slight boost is attributed to strong sales for core immunology treatments and an extended exclusivity window for Rinvoq, in addition to ongoing strategic developments. As analysts evaluate these catalysts alongside lingering concerns, readers should stay tuned for insights on monitoring evolving opinions and updates in the months ahead. Stay updated...",
      "url": "https://finnhub.io/api/news?id=267bd91fae4eeee3938dcab4caaa3ee235f892f5cf537d8514ca1df38202b8cc"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie's (ABBV) Dividend Hike Amid Margin Pressures Shaping Its Investment Appeal?",
    "summary": "AbbVie recently reported third-quarter 2025 results, highlighted by a US$1.32 billion year-on-year increase in sales and a US$0.09 quarterly rise in its cash dividend to US$1.73 per share, but also announced a US$847 million intangible asset impairment and a significant drop in net income compared to the previous year. This period illustrates both AbbVie's ongoing emphasis on shareholder returns and the financial pressures from margin compression and asset write-downs. We'll examine how...",
    "url": "https://finnhub.io/api/news?id=e98d9f344ad9745e59733edeb193b28c3a50a7fa5a70bcee6a98436ec87df4df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762787567,
      "headline": "Is AbbVie's (ABBV) Dividend Hike Amid Margin Pressures Shaping Its Investment Appeal?",
      "id": 137396599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently reported third-quarter 2025 results, highlighted by a US$1.32 billion year-on-year increase in sales and a US$0.09 quarterly rise in its cash dividend to US$1.73 per share, but also announced a US$847 million intangible asset impairment and a significant drop in net income compared to the previous year. This period illustrates both AbbVie's ongoing emphasis on shareholder returns and the financial pressures from margin compression and asset write-downs. We'll examine how...",
      "url": "https://finnhub.io/api/news?id=e98d9f344ad9745e59733edeb193b28c3a50a7fa5a70bcee6a98436ec87df4df"
    }
  },
  {
    "ts": null,
    "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
    "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
    "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762778820,
      "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
      "id": 137394837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
      "url": "https://finnhub.io/api/news?id=16a7a39cbe1e3d6a77b7a44f7c1022483a87f9ccad15040db0e2e6567d3ce4e8"
    }
  },
  {
    "ts": null,
    "headline": "QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer",
    "summary": "CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).",
    "url": "https://finnhub.io/api/news?id=6fe31165f87f8c1c5326a3a766202d45755ed4ea7cd28aec9cc06af9c0ef258b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762778700,
      "headline": "QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer",
      "id": 137394895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).",
      "url": "https://finnhub.io/api/news?id=6fe31165f87f8c1c5326a3a766202d45755ed4ea7cd28aec9cc06af9c0ef258b"
    }
  }
]